Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:MBIO)

1.040 -0.040 (-3.70%)
Streaming Delayed Price Updated: 3:46 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about MBIO

< Previous 1 2 Next >
BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Engages Venture Liquidity Providers for Market-Making Services
Via Investor Brand Network
Topics Artificial Intelligence
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World’s First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening
Via Investor Brand Network
Topics Artificial Intelligence
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Develops Intox Collect(TM) to Scale AI Voice-Based Intoxication Detection
Via Investor Brand Network
Topics Artificial Intelligence
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets South American Mining Sector as Voice-Based Drug and Alcohol Impairment Screening Platform Moves Toward Commercial Deployment
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Mindbio Announces Intention To Refile MD & A
 
Via TheNewswire.com
News headline image
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
Via ACCESSWIRE
News headline image
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
Via ACCESSWIRE
Mindbio Announces Clinical Trial Milestone In Phase 2B Microdosing Trials Targeting Existential Distress, Depression & Anxiety In Advanced Stage Cancer
One of two Phase 2B trials currently dosing and underway: 
Via TheNewswire.com
News headline image
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
Via ACCESSWIRE
News headline image
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
Via ACCESSWIRE
News headline image
Mindbio Therapeutics CEO Issues Letter To Shareholders
Via ACCESSWIRE
News headline image
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
Via ACCESSWIRE
News headline image
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
Via ACCESSWIRE
News headline image
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
Via ACCESSWIRE
News headline image
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
Via ACCESSWIRE
News headline image
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
Via ACCESSWIRE
News headline image
LSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood Issues ↗
 
Via Benzinga
News headline image
Lender Requests to Convert Loan to MindBio Shares
Via ACCESSWIRE
News headline image
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
Via ACCESSWIRE
News headline image
MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Via ACCESSWIRE
News headline image
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
Via ACCESSWIRE
News headline image
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
Via ACCESSWIRE
News headline image
MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
Via ACCESSWIRE
News headline image
MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials
Via ACCESSWIRE
News headline image
MindBio Therapeutics Team Members Honoured with Industry Leading Awards
Via ACCESSWIRE
News headline image
MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer Patients
Via ACCESSWIRE
News headline image
MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients
Via ACCESSWIRE
News headline image
Mindbio Therapeutics Nominated for Company of the Year in Industry Awards
Via ACCESSWIRE
News headline image
MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.